EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ginsenoside reprogramming microglia through the FGF/FGFR1 inhibits post traumatic stress disorder

Huangao Zhou, Hao Pan, Xiangwei Li, Lan Huang, Ruiqi Zhang, Xianliang Yan, Jianing Xu

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2024.113763 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Huangao Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of emergency medicine, The Jiangyin Clinical College of Xuzhou Medical University. Jiangyin, PR China; Department of emergency medicine, J…. Hauptthemen laut MEDLINE: Ginsenosides, Receptor, Fibroblast Growth Factor, Type 1, Stress Disorders, Post-Traumatic, Microglia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Post traumatic stress disorder (PTSD) is a serious and persistent mental diseases. Nowadays, Treatment of PTSD patients in clinical practice is mainly based on drug therapy accompanied by psychological therapy. However, the therapeutic effect is unsatisfactory. It is urgent to detect how to treat PTSD patients. Here, we found that ginsenoside can significantly relieve PTSD symptoms in mice model. Rg3, one of the main pharmacological components of ginsenoside, prevents PTSD by promoting alternatively activated M2 phenotype microglia while inhibiting classically activated inflammatory M1 phenotype microglia. Mechanistically, Rg3 up-regulates fibroblast growth factor receptor 1 (FGFR1) expression in microglia to suppress excessive activation of microglia and reduce neuronal apoptosis. Importantly, knocking down FGFR1 expression in BV2 cells promoted a pro-inflammatory phenotype of BV2 cells, while over-expressing FGFR1 reversed this effect. In vivo PTSD mice model results showed that knockdown FGFR1 prevents the therapeutic effect of Rg3, which indicates that FGFR1 is an essential target of PTSD. Our results reveal that Rg3 may be a potential drug to treat PTSD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GinsenosidesReceptor, Fibroblast Growth Factor, Type 1Stress Disorders, Post-TraumaticMicrogliaMice, Inbred C57BLDisease Models, AnimalAnimalsMaleMiceCell LineHumansApoptosisFibroblast Growth FactorsSignal Transduction

Stichwörter der Autor:innen

FGFR1GinsenosideInflammatoryMicrogliaPost traumatic stress disorder

Substanzen

GinsenosidesReceptor, Fibroblast Growth Factor, Type 1Fgfr1 protein, mouseginsenoside Rg3Fibroblast Growth Factors

Autor:innen und Institutionen

  • Department of emergency medicine, The Jiangyin Clinical College of Xuzhou Medical University. Jiangyin, PR China; Department of emergency medicine, Jiangyin People's Hospital Affiliated to Nantong University. Jiangyin,…
  • Department of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, PR China.
  • Department of emergency medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou, PR China.
  • Department of emergency medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou, PR China. Electronic address: docyxl@163.com.

Zitieren

APA

Zhou, H., Pan, H., Li, X., Huang, L., Zhang, R., Yan, X., & Xu, J. (2025). Ginsenoside reprogramming microglia through the FGF/FGFR1 inhibits post traumatic stress disorder. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113763

Vancouver

Zhou H, Pan H, Li X, Huang L, Zhang R, Yan X, et al. Ginsenoside reprogramming microglia through the FGF/FGFR1 inhibits post traumatic stress disorder. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2024.113763

BibTeX
@article{Zhou2025,
  author = {Zhou, Huangao and Pan, Hao and Li, Xiangwei and Huang, Lan and Zhang, Ruiqi and Yan, Xianliang and Xu, Jianing},
  title = {Ginsenoside reprogramming microglia through the FGF/FGFR1 inhibits post traumatic stress disorder},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2024.113763}
}
Kostenlos starten →